Thumbnail Image
Item

SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement

Alexander, JL
; 
Moran, GW
; 
Gaya, DR
; 
Raine, T
; 
Hart, A
; 
Kennedy, NA
; 
Lindsay, JO
; 
MacDonald, J
; 
Segal, JP
; 
Sebastian, S
... show 10 more
Authors
Alexander, JL
 Moran, GW
 Gaya, DR
 Raine, T
 Hart, A
 Kennedy, NA
 Lindsay, JO
 MacDonald, J
 Segal, JP
 Sebastian, S
 Selinger, CP
 Parkes, M
 Smith, PJ
 Dhar, A
 Subramanian, S
 Arasaradnam, R
 Lamb, CA
 Ahmad, T
 Lees, CW
 Dobson, L
 Wakeman, R
 Iqbal, TH
 Arnott, Ian
 Powell, N
 Inflammatory Bowel Disease section of the British Society of Gastroenterology
 Inflammatory Bowel Disease Clinical Research Group
Editors
Other contributors
Affiliation
Epub Date
Issue Date
2021-01-25
Submitted date
Subjects
SARS‐CoV‐2
 inflammatory bowel disease
Show all metadata
Files
Thumbnail Image
Alexander_et_al_SARS-Cov-2_vaccination_2022.pdf
Adobe PDF, 764.53 KB
Alternative
Abstract
SARS-CoV-2 has caused a global health crisis and mass vaccination programmes provide the best opportunity for controlling transmission and protecting populations. Despite the impressive clinical trial results of the BNT162b2 (Pfizer/BioNTech), ChAdOx1 nCoV-19 (Oxford/AstraZeneca), and mRNA-1273 (Moderna) vaccines, important unanswered questions remain, especially in patients with pre-existing conditions. In this position statement endorsed by the British Society of Gastroenterology Inflammatory Bowel Disease (IBD) section and IBD Clinical Research Group, we consider SARS-CoV-2 vaccination strategy in patients with IBD. The risks of SARS-CoV-2 vaccination are anticipated to be very low, and we strongly support SARS-CoV-2 vaccination in patients with IBD. Based on data from previous studies with other vaccines, there are conceptual concerns that protective immune responses to SARS-CoV-2 vaccination may be diminished in some patients with IBD, such as those taking anti-TNF drugs. However, the benefits of vaccination, even in patients treated with anti-TNF drugs, are likely to outweigh these theoretical concerns. Key areas for further research are discussed, including vaccine hesitancy and its effect in the IBD community, the effect of immunosuppression on vaccine efficacy, and the search for predictive biomarkers of vaccine success.
Citation
Alexander, J. L., Moran, G. W., Gaya, D. R., Raine, T. et al (2021) SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement, The Lancet, 6(3), pp.218-224. https://doi.org/10.1016/S2468-1253(21)00024-8
Publisher
Elsevier
Journal
The Lancet Gastroenterology and Hepatology
Research Unit
URI
http://hdl.handle.net/2436/624833
DOI
10.1016/S2468-1253(21)00024-8
PubMed ID
33508241 (pubmed)
PubMed Central ID
Embedded videos
Additional Links
Type
Journal article
Language
en
Description
This is an accepted manuscript of an article published by Elsevier on 25/01/2021, available online: https://doi.org/10.1016/S2468-1253(21)00024-8 The accepted version of the publication may differ from the final published version.
Series/Report no.
ISSN
2468-1253
EISSN
2468-1253
ISBN
ISMN
Gov't Doc #
Sponsors
CAL acknowledges support from the NIHR Newcastle Biomedical Research Centre. JLA and NP acknowledge funding from the National Institute of Health Research (NIHR) Biomedical Research Centre (BRC) based at Imperial College London and Imperial College Healthcare NHS Trust. JLA is the recipient of a NIHR Academic Clinical Lectureships. JLA receives funding for his Clinical Lectureship from Imperial College London and The Freed Foundation.
Rights
Research Projects
Organizational Units
Journal Issue
Embedded videos
Collections
Faculty of Science and Engineering